UBS AM
MRNA icon

UBS AM’s Moderna MRNA Stock Holding History

UBS AM’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107M Sell
1,521,849
-98,725
-6% -$5.11M 0.02% 507
2026
Q1 		$82.3M Buy
1,620,574
+31,411
+2% +$1.47M 0.02% 542
2025
Q4 		$46.9M Sell
1,589,163
-371,805
-19% -$10.1M 0.01% 619
2025
Q3 		$50.7M Sell
1,960,968
-1,062,259
-35% -$29.6M 0.01% 600
2025
Q2 		$83.4M Sell
3,023,227
-574,009
-16% -$15.1M 0.02% 573
2025
Q1 		$102M Buy
3,597,236
+11,270
+0.3% +$400K 0.03% 529
2024
Q4 		$149M Sell
3,585,966
-304,846
-8% -$14.6M 0.03% 432
2024
Q3 		$260M Buy
3,890,812
+19,819
+0.5% +$1.82M 0.07% 275
2024
Q2 		$460M Buy
3,870,993
+197,950
+5% +$25.1M 0.13% 133
2024
Q1 		$391M Buy
3,673,043
+687,913
+23% +$69.3M 0.14% 145
2023
Q4 		$297M Buy
2,985,130
+562,058
+23% +$47.3M 0.12% 179
2023
Q3 		$250M Buy
2,423,072
+957,566
+65% +$107M 0.11% 183
2023
Q2 		$225M Hold
1,465,506
– – 0.11% 199
2023
Q1 		$225M Buy
1,465,506
+37,179
+3% +$6.13M 0.11% 199
2022
Q4 		$257M Buy
1,428,327
+183,681
+15% +$30M 0.13% 178
2022
Q3 		$147M Buy
1,244,646
+32,649
+3% +$4.95M 0.08% 269
2022
Q2 		$173M Sell
1,211,997
-797
-0.1% -$114K 0.09% 239
2022
Q1 		$209M Sell
1,212,794
-152,211
-11% -$25.6M 0.09% 243
2021
Q4 		$347M Buy
1,365,005
+55,735
+4% +$16.3M 0.13% 169
2021
Q3 		$504M Buy
1,309,270
+111,826
+9% +$41.2M 0.21% 103
2021
Q2 		$281M Buy
1,197,444
+263,480
+28% +$47.1M 0.12% 180
2021
Q1 		$122M Sell
933,964
-1,308
-0.1% -$190K 0.05% 373
2020
Q4 		$97.7M Buy
935,272
+128,836
+16% +$13M 0.05% 412
2020
Q3 		$57.1M Buy
806,436
+84,951
+12% +$5.92M 0.03% 480
2020
Q2 		$46.3M Buy
721,485
+412,859
+134% +$22.6M 0.03% 513
2020
Q1 		$9.24M Sell
308,626
-207,269
-40% -$4.77M 0.01% 878
2019
Q4 		$10.1M Buy
515,895
+37,552
+8% +$666K 0.01% 944
2019
Q3 		$7.62M Buy
+478,343
New +$7.07M 0.01% 1051

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

UBS AM's MRNA Position: Q2 2026 in Review

UBS AM reduced its Moderna (MRNA) stake by 6.1% in Q2 2026, selling an estimated $5.11M and leaving 1,521,849 shares worth $107M. The position accounts for 0.02% of the portfolio, ranked #507.

UBS AM first reported a position in MRNA in Q3 2019 and has held it in 28 quarters since. The position peaked at $504M in Q3 2021. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • UBS AM held 1,521,849 shares of Moderna worth $107M as of Q2 2026.
  • UBS AM sold 98,725 Moderna shares in Q2 2026, an estimated $5.11M.
  • Moderna made up 0.02% of UBS AM's portfolio in Q2 2026, its #507 holding.
  • UBS AM first reported a position in Moderna in Q3 2019 and has held it in 28 quarters since.
  • UBS AM's Moderna position peaked at $504M in Q3 2021.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.